Inflammatory bowel disease (IBD) refers to diseases characterized by chronic inflammation of the gastrointestinal tract. The most common are Crohn’s disease and ulcerative colitis. Chronic chronic inflammation can impair the normal functioning of affected gastrointestinal organs, leading to symptoms such as persistent diarrhea, abdominal pain, rectal bleeding, weight loss… Continue Reading Inflammatory bowel disease in-depth report: current therapies, new drug pipelines and prospects
Alzheimer’s disease is a neurodegenerative disease. Patients will suffer from memory loss, speech impairment, sluggish response, loss of mind, and abnormal behaviors, and even do not know their loved ones. An epidemic Data show that in 2018, 50 million elderly people worldwide suffered from Alzheimer’s disease, and… Continue Reading Who can cure Alzheimer’s disease?
Cancer is one of the leading causes of death worldwide, and distant metastases cause more than 90% of cancer deaths. Due to the limited resolution of imaging technologies such as bioluminescence and MRI, scientists have not been able to comprehensively detect metastatic cells throughout the body, which has greatly… Continue Reading Cell releases blockbuster black technology: fully revealing cancer metastasis
Alzheimer’s disease, commonly known as Alzheimer’s disease, is a neurodegenerative disease. Patients may experience memory loss, language problems, slow response, lost, mental behavior, etc., and even worse, they will not know their loved ones. According to the data, 50 million people in the world suffer from Alzheimer’s disease in… Continue Reading Is the vaccine returning to the development of new drug development for Alzheimer’s disease?
Prostate cancer is a male androgen-dependent tumor. Androgen stimulates the growth of prostate cancer cells and induces disease progression. Metastatic prostatectomy (ADT) is commonly used in patients with metastatic prostate cancer. The initial response rate can reach 80%-90%, but almost all patients will eventually progress to metastatic castration-resistant prostate… Continue Reading Competition pattern of new drug development in advanced prostate cancer
Immunotherapy is considered to be the fourth pillar of cancer treatment (in parallel with surgery, radiotherapy, and chemotherapy), by enhancing the ability of the immune system to target and kill tumor cells, including: 1) Blocking antibodies to the inhibitory immune checkpoint pathway 2) Cell therapy based on dendritic cells… Continue Reading Nature: The next step in cancer immunotherapy is joint therapy. Eradication of cancer is not the ultimate goal.
Bispecific antibody (BsAb) refers to an antibody molecule that can specifically bind two antigens or two epitopes at the same time. In theory, it can exert synergistic effect of two monoclonal antibodies, which is one of the most popular new drug research and development investment direction in the industry.… Continue Reading Bispecific antibody boom
At the end of 2018, Celgene understated the monotherapy of CD47 monoclonal antibody CC-90002 for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). On the day of the suspension of the CC-90002 trial, shares in other CD47 companies such as Trillium, Forty Seven, and Surface… Continue Reading Second generation CD47 antibody: a new hot spot for tumor immunotherapy
“Big Pharmaceuticals” has been committed to producing a wide range of innovative drugs for many years. For them, gene therapy may be the place to give birth to the next “miracle.” Gene therapy, as its name implies, is a treatment that replaces defective genes with normal genes and has… Continue Reading Gene therapy is the leader, attracting countless giants to compete!
On March 7, the New England Journal of Medicine published the results of a Phase I study of BI 655139 in the treatment of generalised pustular psoriasis (GPP). Pustular psoriasis is a rare type of psoriasis, accounting for no more than 1%. It is usually divided into generalized pustular… Continue Reading Boehringer Ingelheim first in class monoclonal antibody is surprisingly effective for rare psoriasis